The role of IL-33 and mast cells in allergy and inflammation

Clinical and Translational Allergy

Marcus Maurer²  Martin K. Church²  Mahejibin Khan¹  Rohit Saluja³ 

[1] Central Food Technological Research Institute-Resource Centre, Lucknow, India;Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany;Ramalingaswami Fellow, Department of Biotechnology, Government of India, New Delhi, India

关键词: Atopic dermatitis;    Allergic asthma;    MAP kinases;    MyD88;    IL-33;    Mast cell;   

Others  :  1230346
DOI  :  10.1186/s13601-015-0076-5

 received in 2015-06-10, accepted in 2015-09-13,  发布年份 2015

【 摘 要 】

Interleukin-33 (IL-33) is a member of the interleukin-1 (IL-1) cytokine family. It is preferentially and constitutively expressed in different structural cells such as epithelial cells, endothelial cells, and smooth muscle cells. During necrosis of these cells (after tissue injury or cell damage), the IL-33 that is released may be recognized by different types of immune cells, such as eosinophils, basophils and, especially, mast cells. IL-33 needs the specific receptor ST2 (membrane-bound receptor) and Interleukin-1 receptor accessory protein heterodimer for its binding, which instigates the production of different types of cytokines and chemokines that have crucial roles in the exacerbation of allergic diseases and inflammation. IL-33 and mast cells have been influentially associated to the pathophysiology of allergic diseases and inflammation. IL-33 is a crucial regulator of mast cell functions and might be an attractive therapeutic target for the treatment of allergic and inflammatory diseases. In this review, we summarize the current knowledge regarding the roles of IL-33 and mast cells in the pathogenesis of allergies and inflammation.

【 授权许可】

   
2015 Saluja et al.

【 图 表 】

Fig.1.

【 参考文献 】

• [1]Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, et al.: Production and functions of IL-33 in the central nervous system. Brain Res 2011, 1385:8-17.
• [2]Liew FY, Pitman NI, McInnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10(2):103-110.
• [3]Miller AM: Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011, 8(1):22. BioMed Central Full Text
• [4]Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, et al.: Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012, 188(7):3488-3495.
• [5]Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23(5):479-490.
• [6]Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al.: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007, 104(1):282-287.
• [7]Moussion C, Ortega N, Girard JP: The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One 2008, 3(10):e3331.
• [8]Wood IS, Wang B, Trayhurn P: IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 2009, 384(1):105-109.
• [9]Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al.: Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010, 125(3):752-754.
• [10]Andronicos NM, McNally J, Kotze AC, Hunt PW, Ingham A: Trichostrongylus colubriformis larvae induce necrosis and release of IL33 from intestinal epithelial cells in vitro: implications for gastrointestinal nematode vaccine design. Int J Parasitol 2012, 42(3):295-304.
• [11]Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, et al.: Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011, 12(7):631-638.
• [12]Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al.: Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464(7293):1367-1370.
• [13]Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al.: Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 2010, 107(25):11489-11494.
• [14]Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al.: Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009, 183(8):5094-5103.
• [15]Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, et al.: Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Investig 2013, 123(9):3967-3982.
• [16]Arshad MI, Piquet-Pellorce C, L’Helgoualc’h A, Rauch M, Patrat-Delon S, Ezan F, et al.: TRAIL but not FasL and TNFalpha, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 2012, 56(6):2353-2362.
• [17]Cayrol C, Girard JP: IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 2014, 31:31-37.
• [18]Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M, et al.: IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol 2013, 190(9):4489-4499.
• [19]Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al.: Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 2014, 40(3):425-435.
• [20]Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, et al.: Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 2011, 23(5):307-315.
• [21]Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H: IL-33-responsive lineage—CD25 + CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012, 188(3):1503-1513.
• [22]Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Kawagoe T, Imoto Y, et al.: A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol 2012, 130(1):184 e11-194 e11.
• [23]Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al.: A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 2013, 210(13):2939-2950.
• [24]Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al.: Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010, 463(7280):540-544.
• [25]Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al.: Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011, 12(11):1055-1062.
• [26]Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S: IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010, 59(2):143-160.
• [27]Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL: Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007, 13(7):851-856.
• [28]Cayrol C, Girard JP: The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009, 106(22):9021-9026.
• [29]Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, Joosten LA: Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol 2015, 33:49-77.
• [30]Martin MU: Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol 2013, 25(6):449-457.
• [31]Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, et al.: Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010, 37(1):18-25.
• [32]Le Goffic R, Arshad MI, Rauch M, L’Helgoualc’h A, Delmas B, Piquet-Pellorce C, et al.: Infection with influenza virus induces IL-33 in murine lungs. Am J Respir Cell Mol Biol 2011, 45(6):1125-1132.
• [33]Kouzaki H, Iijima K, Kobayashi T, O’Grady SM, Kita H: The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 2011, 186(7):4375-4387.
• [34]Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al.: Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31(1):84-98.
• [35]Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G: Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009, 284(29):19420-19426.
• [36]Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, et al.: Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009, 183(12):7890-7897.
• [37]Lingel A, Weiss TM, Niebuhr M, Pan B, Appleton BA, Wiesmann C, et al.: Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors—insight into heterotrimeric IL-1 signaling complexes. Structure 2009, 17(10):1398-1410.
• [38]Lefrancais E, Cayrol C: Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw 2012, 23(4):120-127.
• [39]Roy A, Ganesh G, Sippola H, Bolin S, Sawesi O, Dagalv A, et al.: Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J Biol Chem 2014, 289(1):237-250.
• [40]Cascao R, Rosario HS, Souto-Carneiro MM, Fonseca JE: Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010, 9(8):531-535.
• [41]Fournier BM, Parkos CA: The role of neutrophils during intestinal inflammation. Mucosal Immunol 2012, 5(4):354-366.
• [42]Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA: IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179(4):2551-2555.
• [43]Funakoshi-Tago M, Tago K, Hayakawa M, Tominaga S, Ohshio T, Sonoda Y, et al.: TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 2008, 20(9):1679-1686.
• [44]Saluja R, Ketelaar ME, Hawro T, Church MK, Maurer M, Nawijn MC: The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol 2015, 63(1):80-85.
• [45]Saluja R, Hawro T, Eberle J, Church MK, Maurer M: Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. J Biol Regul Homeost Agents 2014, 28(4):575-585.
• [46]Enoksson M, Lyberg K, Moller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C: Mast cells as sensors of cell injury through IL-33 recognition. J Immunol 2011, 186(4):2523-2528.
• [47]Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al.: IL-33 induces antigen-specific IL-5 + T cells and promotes allergic-induced airway inflammation independent of IL-4. Journal of immunology. 2008, 181(7):4780-4790.
• [48]Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, et al.: Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice. Allergy 2012, 67(9):1118-1126.
• [49]Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al.: IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007, 87(10):971-978.
• [50]Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al.: IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008, 105(31):10913-10918.
• [51]Schneider E, Petit-Bertron AF, Bricard R, Levasseur M, Ramadan A, Girard JP, et al.: IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol 2009, 183(6):3591-3597.
• [52]Cho KA, Suh JW, Sohn JH, Park JW, Lee H, Kang JL, et al.: IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol 2012, 302(4):L429-L440.
• [53]Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y: Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002, 32(10):1520-1526.
• [54]Hayakawa H, Hayakawa M, Kume A, Tominaga S: Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282(36):26369-26380.
• [55]Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, et al.: Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999, 190(7):895-902.
• [56]Kearley J, Buckland KF, Mathie SA, Lloyd CM: Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009, 179(9):772-781.
• [57]Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T: Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009, 386(1):181-185.
• [58]Sjoberg LC, Gregory JA, Dahlen SE, Nilsson GP, Adner M: Interleukin-33 exacerbates allergic bronchoconstriction in the mice via activation of mast cells. Allergy 2015, 70(5):514-521.
• [59]Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY: IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 2010, 185(6):3472-3480.
• [60]Lee HY, Rhee CK, Kang JY, Byun JH, Choi JY, Kim SJ, et al.: Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp Lung Res 2014, 40(2):66-76.
• [61]Raeiszadeh Jahromi S, Mahesh PA, Jayaraj BS, Madhunapantula SR, Holla AD, Vishweswaraiah S, et al.: Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: a case-control study. J Asthma 2014, 51(10):1004-1013.
• [62]Kaur D, Gomez E, Doe C, Berair R, Woodman L, Saunders R, et al.: IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy 2015, 70(5):556-567.
• [63]Shimizu M, Matsuda A, Yanagisawa K, Hirota T, Akahoshi M, Inomata N, et al.: Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005, 14(19):2919-2927.
• [64]Savinko T, Matikainen S, Saarialho-Kere U, Lehto M, Wang G, Lehtimaki S, et al.: IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 2012, 132(5):1392-1400.
• [65]Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M: Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol 2012, 132(11):2593-2600.
• [66]Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al.: Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 2013, 110(34):13921-13926.
• [67]Cevikbas F, Steinhoff M: IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol 2012, 132(5):1326-1329.
• [68]Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A, et al.: Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011, 31(9):2080-2089.
• [69]Masamune A, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T: Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2010, 299(4):G821-G832.
• [70]Velickovic M, Pejnovic N, Petrovic R, Mitrovic S, Jeftic I, Kanjevac T, et al.: Expression of interleukin-33 and its receptor ST2 in periapical granulomas and radicular cysts. J Oral Pathol Med 2015.
• [71]Kay AB, Clark P, Maurer M, Ying S: Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol 2014.
• [72]Tong X, Lu F: IL-33/ST2 involves the immunopathology of ocular toxoplasmosis in murine model. Parasitol Res 2015, 114(5):1897-1905.
• [73]Tjota MY, Hrusch CL, Blaine KM, Williams JW, Barrett NA, Sperling AI: Signaling through FcRgamma-associated receptors on dendritic cells drives IL-33-dependent TH2-type responses. J Allergy Clin Immunol 2014, 134(3):706 e8-713 e8.
• [74]Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al.: IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007, 82(6):1481-1490.
• [75]Andrade MV, Iwaki S, Ropert C, Gazzinelli RT, Cunha-Melo JR, Beaven MA: Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol 2011, 41(3):760-772.
• [76]Yang Z, Sun R, Grinchuk V, Fernandez-Blanco JA, Notari L, Bohl JA, et al.: IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent. Am J Physiol Gastrointest Liver Physiol 2013, 304(4):G381-G389.
• [77]Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al.: Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008, 20(6):791-800.
• [78]Tung HY, Plunkett B, Huang SK, Zhou Y: Murine mast cells secrete and respond to interleukin-33. J Interferon Cytokine Res 2014, 34(3):141-147.
• [79]Matsuda A, Okayama Y, Terai N, Yokoi N, Ebihara N, Tanioka H, et al.: The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009, 50(10):4646-4652.